What question did this study set out to answer?

This research aims to evaluate the outcomes of SGLT2 inhibitor therapy in myocardial infarction patients, focusing on sex differences.

January 10, 2026European journal of medical research0 citationsOpen Access

Sex-consistent outcomes in SGLT2 inhibitor-treated acute myocardial infarction patients: a real-world study

CGChen GuoSecond Affiliated Hospital of Xi'an Jiaotong University JDJia-Hao DouSecond Affiliated Hospital of Xi'an Jiaotong University FGFan-Shun GuoSecond Affiliated Hospital of Xi'an Jiaotong University

Key Result

In patients with acute myocardial infarction, early initiation of SGLT2 inhibitors resulted in sex-independent clinical outcomes with no significant disparities.

Key Points

This research aims to evaluate the outcomes of SGLT2 inhibitor therapy in myocardial infarction patients, focusing on sex differences.
Analyzed outcomes of patients treated with SGLT2 inhibitors post-acute myocardial infarction
Evaluated cardiorenal and metabolic outcomes
Compared results between male and female patients
Outcomes were consistent regardless of sex
No significant sex disparities were noted in cardiorenal-metabolic results

Structured PICO

Does early SGLT2 inhibitor initiation have sex-independent effects on cardiorenal-metabolic and clinical outcomes in patients with acute myocardial infarction?

Population

310 adults (aged 18 to 80 years) diagnosed with acute myocardial infarction who underwent percutaneous coronary intervention (PCI) and had indications of diabetes and/or heart failure. The cohort included 244 males (median age 61) and 66 females (median age 70). Key exclusions: history of prior oral SGLT2 inhibitor use, renal insufficiency (eGFR < 30 mL/min/1.73 m2), pregnancy, lactation, or history of malignancy within the past three years.

Intervention

Early initiation of an SGLT2 inhibitor (empagliflozin or dapagliflozin) within 72 hours of the onset of myocardial infarction, added to guideline-directed medical therapy.

Comparator

Male vs. female patients (no conventional treatment control group; all patients received SGLT2 inhibitors).

Outcome

proBNP levels and left ventricular ejection fraction (LVEF) measured during multiple follow-up visits over two years.surrogate

Early initiation of SGLT2 inhibitors in patients with acute myocardial infarction provides comparable long-term cardiorenal and metabolic benefits regardless of sex, supporting their broad use in this population.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Among patients with acute myocardial infarction treated with early SGLT2 inhibitor initiation, cardiorenal-metabolic and primary clinical outcomes are sex-independent, indicating no significant sex disparities in outcomes of SGLT2 inhibitor therapy.

问 AI

Bookmark

View Full Paper